MARCH 26, 2020
Targeting ACE2 as a Therapy for COVID-19 Patients
The scientific team at PEARKO Therapeutics is developing therapies to treat COVID-19 patients by targeting ACE2.
READ MORE-
Targeting ACE2 as a Therapy ForCOVID-19 PATIENTSLEARN MORE -
Innovative Pharmocological Therapies
FOR CARDIOVASCULAR DISEASES -
Our Lead Project:APELIN ANALOG THERAPYLEARN MORE
To provide pharmacological therapies to patients with cardiovascular disease through innovative technologies.
We engage in the bench-to-bedside approach to medicine to accelerate in development of effective biotechnologies.
Keep up to date with our latest innovations, including Apelin Analog therapy.
Support us as we push the boundaries of medicine.
Company News
OCTOBER 23, 2019
2019 Innovation Award Recipient
PEARKO Therapeutics thanks TEC Edmonton and their supporters for recognizing our achievement at the 2019 Innovation Awards, as an established spinoff company.
TEC EDMONTON
SEPTEMBER 27, 2019
Creative Destruction Lab
PEARKO Therapeutics is proud to announce their acceptance into the Creative Destruction Lab Health Stream in Toronto.
CDL WEBSITE
MAY 21, 2019
Apelin Analog Protects Against Vascular Disease
Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs.
READ ARTICLE
OUR LEAD PROJECT
Apelin Analogs
Activation of cardioprotective pathways to treat patients with heart failure, myocardial infarction, and pulmonary arterial hypertension.
ONGOING PROJECT
Angiotensin 1-7 Analogs
Cardiometabolic therapeutic agents to treat heart failure with preserved and reduced ejection fraction.
ONGOING PROJECT
ADAM17 Inhibitors
Inhibition of enzyme activity to prevent aortic aneurysm.